|1.||Yanagihara, Katsunori: 4 articles (06/2013 - 01/2006)|
|2.||Kohno, Shigeru: 4 articles (06/2013 - 01/2006)|
|3.||Yasuda, Mitsuru: 3 articles (01/2015 - 06/2012)|
|4.||Ito, Shin: 3 articles (01/2015 - 06/2012)|
|5.||Kaku, Mitsuo: 3 articles (10/2013 - 06/2013)|
|6.||Tanigawara, Yusuke: 3 articles (10/2013 - 06/2013)|
|7.||Hori, Seiji: 3 articles (06/2013 - 08/2009)|
|8.||Ikeda, Tetsuya: 2 articles (04/2015 - 12/2012)|
|9.||Kohno, Naoyuki: 2 articles (04/2015 - 12/2012)|
|10.||Deguchi, Takashi: 2 articles (01/2015 - 06/2012)|
06/01/2013 - "We evaluated the clinical and bacteriological efficacy of oral sitafloxacin (STFX) in clinically diagnosed community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae. "
09/01/2009 - "In vivo efficacy of sitafloxacin in a new murine model of non-typeable Haemophilus influenzae pneumonia by sterile intratracheal tube."
06/01/2013 - "Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial."
01/01/2006 - "Our results suggest that DX-619 and sitafloxacin are potent against both PSSP and PRSP in our mouse pneumonia model."
09/01/2009 - "The efficacy of sitafloxacin was compared with ciprofloxacin using the new murine pneumonia model. "
12/01/1994 - "DU-6859a exerted significant efficacy against infections caused by M. "
10/01/2000 - "Sitafloxacin was effective in VRE and some recalcitrant MRSA infections."
10/01/2015 - "Sitafloxacin may be considered an alternative drug of choice in treating CRAB related infections."
10/01/2015 - "Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm - author's reply."
10/01/2015 - "Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm."
10/01/2013 - "Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis."
06/01/2012 - "We treated 89 males with NGU, including 15 patients with persistent or recurrent NGU and 1 patient with post-gonococcal urethritis, with a 100-mg twice-daily dose regimen of sitafloxacin to assess its efficacy against NGU. "
06/01/2012 - "Clinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with a 100-mg twice-daily dose regimen of sitafloxacin."
04/16/2011 - "Noncomparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, C. "
01/01/1998 - "We evaluated the efficacy of a new quinolone, DU-6859a, using a new model of rat uterine endometritis. "
01/01/1998 - "These results suggest that DU-6859a would be useful for treating polymicrobial infections in uterine endometritis."
01/01/1998 - "Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis."
|5.||Respiratory Tract Infections (Respiratory Tract Infection)
10/01/2013 - "An optimal dosage regimen of sitafloxacin was considered based on a pharmacokinetics and pharmacodynamics (PK-PD) analysis in patients with community-acquired respiratory tract infections (RTI). "
10/01/2013 - "Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections."
06/01/2013 - "Patients with respiratory tract infections caused by pneumococci were orally treated with sitafloxacin (100 mg qd or 50 mg bid) for 7 days. "
06/01/2013 - "Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections."
10/01/2011 - "[Efficacy and safety of sitafloxacin for lower respiratory tract infections]."
|3.||imipenem drug combination cilastatin (Primaxin)
|7.||sparfloxacin (AT 4140)